New Zealand markets open in 7 hours 52 minutes

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
220.52-5.39 (-2.39%)
At close: 04:00PM EST
221.04 +0.52 (+0.24%)
After hours: 07:50PM EST
Full screen
Trade prices are not sourced from all markets
Previous close225.91
Bid221.19 x 1100
Ask230.00 x 800
Day's range220.30 - 226.37
52-week range217.10 - 468.55
Avg. volume1,583,050
Market cap32.393B
Beta (5Y monthly)0.42
PE ratio (TTM)21.58
EPS (TTM)10.22
Earnings date03 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est284.20
  • Motley Fool

    Is Biogen a Buy?

    Over the past year, shares of Biogen (NASDAQ: BIIB) have dropped by 13.25% while the S&P 500 has climbed by 23.74%. The biotech's poor performance might come as a bit of a surprise since last year its Alzheimer's disease (AD) drug Aduhelm became the first medicine approved in the U.S. for the illness since 2003. Do the company's recent woes represent a buying opportunity or should investors stay away?

  • Zacks

    Ionis' (IONS) Partner to Begin New Huntington's Disease Study

    Ionis' (IONS) partner, Roche, is planning a new phase II study to evaluate tominersen for the treatment of Huntington's disease.

  • Motley Fool

    Is Biogen a Buy After the Latest Aduhelm Disaster?

    Biogen's (NASDAQ: BIIB) stock is taking yet another body blow since the Centers for Medicare and Medicaid Services (CMS) issued a draft ruling on Jan. 12 that the company's troubled new Alzheimer's drug, Aduhelm, wouldn't be covered by the U.S. public insurance plans except in the context of patients enrolled in clinical trials. In my view, there isn't much hope for Aduhelm's fortunes to reverse anytime soon.